UNSPSC 51282509: Cefazaflur

This classification denotes a cephalosporin antibiotic with the molecular formula C13H13F3N6O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 97I0692RNT chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-7-((((trifluoromethyl)thio)acetyl)amino)-, (6r-trans)- but generally known as cefazaflur, which bears US NIH Compound Identifier 40239.

UNSPSC 51282509 Cefazaflur is a Commodity code that nominally refers to a specific pharmaceutical product, but recent state and local solicitations tagged under this code show minimal alignment with that narrow definition. Instead, the code is appearing in procurement for emergency medical supplies, naloxone, pharmacy benefit programs, and generic pharmaceuticals—a mismatch that signals the code sees little relevant recent activity and may reflect cataloging inconsistency rather than genuine buying patterns for cefazaflur itself. The issuing bodies include county health departments, state health and human services commissions, city fire departments, and multi-state cooperative purchasing alliances, reflecting the broad range of public health and emergency response organizations sourcing medical and pharmaceutical products.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, with quarterly deliveries due by July 26, 2026. The City of Tampa's Purchasing Department posted an IFB in March 2026 for medical and first aid supplies totaling an estimated $700,000 for the Tampa Fire Department Rescue Division, limited to certified Small Local Business Enterprises with a 5% bid discount, with response due March 13, 2026. The Texas Health and Human Services Commission issued a Request for Information in March 2026 exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code's weak connection to actual procurement activity suggests it carries low decision relevance for vendors in the cefazaflur space.